Држава: Велика Британија
Језик: Енглески
Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)
Cefuroxime sodium
Bowmed Ibisqus Ltd
J01DC02
Cefuroxime sodium
250mg
Powder for solution for injection
Intravenous; Intramuscular
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010201; GTIN: 5060130130485
PACKAGE LEAFLET: INFORMATION FOR THE USER CEFUROXIME 250MG POWDER FOR INJECTION CEFUROXIME SODIUM READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Cefuroxime Injection is and what it is used for 2. What you need to know before you are given Cefuroxime Injection 3. How Cefuroxime Injection is given 4. Possible side effects 5. How to store Cefuroxime Injection 6. Contents of the pack and other information 1. WHAT CEFUROXIME INJECTION IS AND WHAT IT IS USED FOR Cefuroxime is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins. Cefuroxime is used to treat infections of: • the lungs or chest • the urinary tract • the skin and soft tissue • the abdomen Cefuroxime is also used: • to prevent infections during surgery. Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to Cefuroxime during your treatment. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN CEFUROXIME INJECTION YOU MUST NOT BE GIVEN CEFUROXIME INJECTION: • If you are allergic to any cephalosporin antibiotics • If you have had a severe allergic reaction to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems) Tell your doctor before you start on Cefuroxime if you think that this applies to you. You must not be given Cefuroxime Injection. WARNINGS AND PRECAUTIONS You must look out for certain symptoms such as allergic reactions, skin rashes, gastrointestinal disorders such as diarrhoea or fungal infections while you are being given Cefuroxime. This will reduce the risk of possible problems. See (‘ Прочитајте комплетан документ
OBJECT 1 CEFUROXIME 250MG POWDER FOR INJECTION VIALS Summary of Product Characteristics Updated 01-Jun-2020 | Bowmed Ibisqus Limited • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Cefuroxime 250mg Powder for Injection 2. Qualitative and quantitative composition Each vial contains 250mg cefuroxime (as sodium salt) 3. Pharmaceutical form Powder for solution for injection Powder for suspension for injection Vial containing white or almost white sterile powder 4. Clinical particulars 4.1 Therapeutic indications Cefuroxime 250mg Powder for Injection is indicated for the treatment of the infections listed below in adults and children including neonates (from birth) (see sections 4.4 and 5.1). • Community acquired pneumonia. • Acute exacerbations of chronic bronchitis. • Complicated urinary tract infections, including pyelonephritis. • Soft-tissue infections: cellulitis, erysipelas and wound infections. • Intra-abdominal infections (see section 4.4). • Prophylaxis Прочитајте комплетан документ